UCB (EBR:UCB) UCB Media Room: acquisitions and disposals of own shares

Directive transparence : information réglementée

12/03/2021 20:03
https://mb.cision.com/Public/18595/3305765/8f2d8237f5dbdc5b_800x800ar.jpg ** Acquisitions of own shares and disposals of own shares ------------------------------------------------------------ Brussels (Belgium), 12 March 2021 =E2=80=93 20:00 (CET) =E2=80=93 regulated= information Acquisitions of own shares In accordance with article 8:4 of the Royal Decree of 29 April 2019 executi= ng the Belgian Code on Companies and Associations, UCB SA/NV (=E2=80=9CUCB= =E2=80=9D or the =E2=80=9CCompany) (Euronext Brussels: UCB) hereby disclose= s certain information in relation to its Share Repurchase Program 2021.=C2= =A0 Under this program, UCB has requested a financial intermediary to repurchas= e up to 750 000 UCB shares on its behalf under the terms of an initial disc= retionary mandate agreement with validity until 25 June 2021, effective as = from 8 March 2021, to cover current and future obligations under UCB's Long= Term Incentive Plans for its personnel. In the framework of this Share Repurchase Program 2021, UCB repurchased 147= 138 UCB shares on Euronext Brussels in the period from 8 March 2021 up to = and including 11 March 2021, as follows:=C2=A0 https://mb.cision.com/Public/18595/3305765/aef124c7e75cdd29_800x800ar.png Disposal of own shares In accordance with article 8:6 of the Royal Decree executing the Belgian Co= de of Companies and Associations, UCB announces that, following exercises o= f stock options by members of its personnel, it has disposed of UCB shares = OTC in view of deliveries of these shares to the relevant members of the pe= rsonnel, within the framework of the Long Term Incentive Program of the UCB= Group, as follows: https://mb.cision.com/Public/18595/3305765/895623beb94d5b02_800x800ar.png This press release is available on UCB SA/NV=E2=80=99s website via the foll= owing link (https://www.ucb.com/stories-media/Press-Releases) . Investor Relations Antje Witte =C2=A0 =C2=A0 =C2=A0 =C2=A0 =C2=A0 Investor Relations, UCB T +32.2.559.94.14 antje.witte@ucb.com Isabelle Ghellynck, =C2=A0Investor Relations, UCB T+32.2.559.9588, isabelle.ghellynck@ucb.com=C2=A0 About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With more than 8 000 people op= erating=C2=A0in approximately 40 countries, the company generated revenue o= f =E2=82=AC 5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol= : UCB). Follow us on Twitter: @UCB_news GenericFile 20210312 - UCB Acquisitions and disposals of own shares ENG final (https://= mb.cision.com/Public/18595/3305765/a96be8930484c1fd.pdf) GenericFile 20210312 - Rachat et ali=C3=A9nation d actions propres FR (https://mb.cisio= n.com/Public/18595/3305765/aef8bba52a5dc59e.pdf) GenericFile 20210312 - Verwerving en vervreemding van eigen aandelen NED (https://mb.ci= sion.com/Public/18595/3305765/8cdc18c2311f787f.pdf) Image Chart 1 March 12 2021 (https://mb.cision.com/Public/18595/3305765/aef124c7e= 75cdd29_org.png) Image Chart 2 March 12 2021 (https://mb.cision.com/Public/18595/3305765/895623beb= 94d5b02_org.png)=0D =0D ______________________=0D If you would rather not receive future communications from UCB SA, please g= o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x63885x1x6868579x24000= x6&Email=3Dregnews%40symexglobal.com.=0D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=